Neuronetics (STIM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
9 Apr, 2026Executive summary
Annual meeting scheduled for May 28, 2026, to be held virtually, with four key proposals up for shareholder vote, including director elections, auditor ratification, executive compensation advisory, and approval of a new equity incentive plan.
Only shareholders of record as of March 30, 2026, are eligible to vote; voting can be done online, by phone, mail, or during the meeting.
Proxy materials, including the annual report and proxy statement, are available online for review.
Voting matters and shareholder proposals
Proposal 1: Election of seven directors, all current members, to serve until the next annual meeting.
Proposal 2: Ratification of KPMG LLP as independent registered public accounting firm for 2026.
Proposal 3: Advisory (non-binding) vote on executive compensation (Say on Pay).
Proposal 4: Approval of the 2026 Equity Incentive Plan, replacing the 2018 plan for future grants.
Board recommends voting “For” all proposals.
Board of directors and corporate governance
Board consists of seven members, with a majority deemed independent under Nasdaq rules.
Board leadership is separated, with an independent Chair distinct from the CEO.
Committees include Audit, Compensation, and Nominating and Corporate Governance, all composed of independent directors.
Board diversity matrix shows representation across gender and ethnic backgrounds.
Stockholder communications and director nomination procedures are established.
Latest events from Neuronetics
- Votes sought for director elections, auditor ratification, compensation, and equity plan.STIM
Proxy filing9 Apr 2026 - Q4 2025 delivered strong revenue growth and cash flow, with robust 2026 growth outlook.STIM
Q4 202518 Mar 2026 - Over 20 million shares registered for resale post-acquisition, with no proceeds to the company.STIM
Registration Filing17 Mar 2026 - Acquisition and integration of Greenbrook TMS set the stage for growth and operational synergies.STIM
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Record growth in new patient starts and adolescent market expansion set stage for 2025 breakeven.STIM
The 44th Annual William Blair Growth Stock Conference1 Feb 2026 - Q2 revenue fell 7% as net loss widened, but a major merger and new financing support future growth.STIM
Q2 20241 Feb 2026 - Q3 revenue up 4% to $18.5M; Greenbrook deal approved, cost synergies, break-even by 2025.STIM
Q3 202415 Jan 2026 - Greenbrook deal closing soon, with major cost synergies and utilization growth ahead.STIM
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026 - Q4 revenue up 11% to $22.5M; 2025 targets $145–$155M revenue and cash flow positivity by Q3.STIM
Q4 202426 Dec 2025